Agreement - January 27, 2020
AstraZeneca to recover the global rights to brazikumab
AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC). Expected to complete in the first quarter of 2020 AstraZeneca and Allergan will terminate their existing license agreement and […]
Agreement - October 3, 2016
AstraZeneca in agreement with Allergan
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070. MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease (a chronic inflammatory disease of the intestines) and is ready for […]
Global report - April 6, 2016
Pfizer and Allergan terminate $160bn merger
Pfizer and Allergan have terminated their $160bn merger, blaming a crack-down this week on tax inversions deal by the US Treasury Department for scuppering what would have marked the largest-ever healthcare acquisition, reports The Telegraph. Tax avoidance schemes such as inversion deals, in which US companies move their legal addresses overseas to take advantage of lower tax rates, have long been a thorn in the […]
Collaboration - February 9, 2016
Allergan and AstraZeneca collaborate
Allergan has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo βlactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae (CRE), for which there are currently very limited […]
Acquisition - December 12, 2015
Global report: Pfizer buys Allergan
In the end of November, Pfizer acquired Allergan for more than $150 billion, a deal which will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector, involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less […]
Acquisition - November 23, 2015
Pfizer buys Allergan
Pfizer has acquired Allergan for more than $150 billion, a deal that will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector and involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less than 10 percent of the […]
